Brooks Laboratories Ltd Valuation Shifts: From Very Attractive to Fair Amidst Sector Challenges

Valuation Metrics: A Closer Look

As of 19 Feb 2026, Brooks Laboratories Ltd trades at a price of ₹76.35, up 4.08% from the previous close of ₹73.36. The stock’s 52-week range spans from ₹59.00 to ₹165.95, indicating significant volatility over the past year. The company’s price-to-earnings (P/E) ratio currently stands at 10.41, a figure that has contributed to the recent downgrade in its valuation grade from very attractive to fair.

The price-to-book value (P/BV) ratio is 1.94, suggesting the stock is trading close to twice its book value. While this is not excessively high, it is a departure from the more compelling valuations seen in the past. Other valuation multiples such as EV to EBIT (36.43) and EV to EBITDA (29.25) remain elevated, reflecting the market’s cautious stance on the company’s earnings quality and operational efficiency.

Comparative Peer Analysis

When compared to its peers within the Pharmaceuticals & Biotechnology sector, Brooks Laboratories’ valuation appears more moderate. For instance, Bliss GVS Pharma trades at a P/E of 21.99 and EV/EBITDA of 16.23, both higher than Brooks, yet it is also graded as fair. On the other hand, companies like Shukra Pharma and NGL Fine Chem are classified as very expensive, with P/E ratios exceeding 40 and EV/EBITDA multiples above 25.

Interestingly, TTK Healthcare is rated attractive despite a higher P/E of 19.07, largely due to its robust PEG ratio of 8.11, signalling strong growth expectations. Brooks’ PEG ratio is an exceptionally low 0.05, which typically indicates undervaluation relative to growth, but this metric alone has not been sufficient to maintain a very attractive valuation grade.

Financial Performance and Returns

Brooks Laboratories’ return profile over various time horizons reveals a mixed picture. The stock has underperformed the Sensex significantly over the past year, with a negative return of -34.85% compared to the Sensex’s 10.22%. Over three years, the stock is down 21.62%, while the benchmark index has surged 37.26%. Even over a decade, Brooks has delivered a modest negative return of -4.19%, starkly contrasting with the Sensex’s impressive 254.07% gain.

Despite these challenges, the company’s return on capital employed (ROCE) is 5.90%, and return on equity (ROE) stands at 12.08%. These figures, while positive, are modest and may explain the cautious valuation stance by the market. The absence of a dividend yield further limits the stock’s appeal to income-focused investors.

Market Capitalisation and Mojo Score Insights

Brooks Laboratories holds a market cap grade of 4, indicating a mid-sized market capitalisation relative to its sector peers. Its Mojo Score, a composite measure of fundamentals, valuation, and momentum, is 32.0, which corresponds to a Sell rating. This is an improvement from a previous Strong Sell grade assigned on 16 Feb 2026, signalling a slight positive shift in the company’s outlook, albeit still on the cautious side.

The downgrade in valuation grade from very attractive to fair reflects the market’s reassessment of the stock’s price attractiveness amid evolving fundamentals and sector dynamics. Investors should note that while the valuation is no longer compellingly cheap, it is not overvalued either, positioning Brooks Laboratories in a neutral zone for potential entry.

Sector and Industry Context

The Pharmaceuticals & Biotechnology sector continues to face headwinds from regulatory pressures, pricing challenges, and competitive intensity. Brooks Laboratories’ valuation and performance must be viewed against this backdrop. Peers with stronger growth prospects or more robust profitability metrics command premium valuations, while those with riskier profiles or weaker financials trade at discounts or are labelled risky.

Brooks’ EV to capital employed ratio of 1.89 and EV to sales of 2.61 suggest moderate capital efficiency and revenue valuation, but the elevated EV to EBIT and EBITDA multiples highlight concerns about earnings sustainability. Investors should weigh these factors carefully when considering the stock’s risk-reward profile.

Price Attractiveness: What Has Changed?

The transition from a very attractive to a fair valuation grade is primarily driven by the relative increase in the P/E ratio and the price-to-book value. Historically, Brooks Laboratories traded at lower multiples, which attracted value investors seeking bargains in the pharmaceuticals space. The current P/E of 10.41, while still below many peers, is higher than its historical lows, signalling that some of the previous undervaluation has been corrected.

Moreover, the P/BV ratio nearing 2 suggests the market is pricing in moderate growth expectations and some improvement in asset utilisation. However, the company’s modest ROCE and ROE figures temper enthusiasm, as they indicate limited efficiency in generating returns from capital and equity.

Investors should also consider the stock’s price momentum. Despite a 4.08% gain on the day of reporting, the stock’s one-week return is negative at -2.37%, and the year-to-date return is down 4.86%, both underperforming the Sensex. This weak momentum may justify the cautious valuation stance.

Investment Implications

For investors, Brooks Laboratories presents a mixed bag. The fair valuation grade suggests the stock is no longer a bargain buy but remains reasonably priced relative to its fundamentals and sector peers. The low PEG ratio of 0.05 hints at potential undervaluation relative to growth, but the company’s subdued profitability and returns metrics warrant prudence.

Given the stock’s underperformance relative to the broader market and the sector’s challenges, investors should carefully assess their risk tolerance and investment horizon before committing capital. Those seeking exposure to the pharmaceuticals sector might consider Brooks Laboratories as a hold or selective buy, depending on their conviction in the company’s turnaround prospects and pipeline developments.

Meanwhile, investors prioritising growth and stronger financial health may find more attractive opportunities among peers with higher ROCE, ROE, and more compelling valuation metrics.

Conclusion

Brooks Laboratories Ltd’s shift from a very attractive to a fair valuation grade reflects a recalibration of market expectations amid evolving fundamentals and sector dynamics. While the stock remains reasonably priced compared to many peers, its modest returns and profitability metrics suggest caution. Investors should balance the company’s valuation parameters with its financial performance and sector outlook to make informed decisions.

As always, a comprehensive analysis incorporating both quantitative metrics and qualitative factors is essential when evaluating stocks in the Pharmaceuticals & Biotechnology sector, where regulatory and competitive risks remain significant.

Limited Period Only. Start at Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Get 71% Off →